1 result
  • reblozyl

    (Luspatercept)
    Celgene Corporation
    REBLOZYL is indicated for treating anemia in adult patients with beta thalassemia and those with very low- to intermediate-risk myelodysplastic syndromes (MDS), either ESA-naïve or after failure of erythropoiesis stimulating agents. It requires red blood cell transfusions but is not a substitute for immediate transfusions.